{{Rsnum
|rsid=80338785
|Chromosome=17
|Orientation=minus
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene=SCN4A
|position=63959270
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=SCN4A
}}{{omim
|id=603967
|rsnum=80338785
|variant=0017
}}
{{omim
|id=603967
|rsnum=80338785
|variant=0020
}}{{ClinVar
|rsid=80338785
|Reversed=1
|FwdREF=C
|FwdALT=A,G,T
|REF=G
|ALT=A,C,T
|RSPOS=62036630
|CHROM=17
|dbSNPBuildID=131
|SSR=0
|SAO=1
|VP=0x050168000000000002110104
|GENEINFO=SCN4A:6329
|GENE_NAME=SCN4A
|GENE_ID=6329
|WGT=0
|VC=SNV
|CLNALLE=1; 2; 3
|CLNHGVS=NC_000017.10:g.62036630G>A; NC_000017.10:g.62036630G>C; NC_000017.10:g.62036630G>T
|CLNSRC=GeneReviews; OMIM Allelic Variant
|CLNORIGIN=0; 1
|CLNSRCID=NBK1338; 603967.0017; 603967.0020
|CLNCUI=CN031165,C2750061; CN031165,CN031165
|CLNDBN=Hypokalemic periodic paralysis 1; Hypokalemic periodic paralysis, type 2
|Disease=Hypokalemic periodic paralysis 1; Hypokalemic periodic paralysis
|CLNACC=RCV000020263.1; RCV000006276.2; RCV000020262.1; RCV000006279.2; RCV000020261.1
|Tags=RV;PM;PMC;SLO;OTHERKG;LSD;OM;NOV
|CLNDSDB=GeneReviews:GeneReviews:MedGen:OMIM:Orphanet; GeneReviews:MedGen:OMIM:Orphanet
|CLNDSDBID=NBK1338:NBK1496:CN031165:170400:681; NBK1338:C2750061:613345:681
|CLNSIG=5
}}{{PMID Auto
|PMID=11558801
|Title=Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis.
}}

{{PMID Auto
|PMID=11591859
|Title=Sodium channel gene mutations in hypokalemic periodic paralysis: an uncommon cause in the UK.
}}

{{PMID Auto
|PMID=15557532
|Title=SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide.
}}

{{PMID Auto
|PMID=10944223
|Title=Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current.
|OA=1
}}

{{PMID Auto
|PMID=15482957
|Title=Mutation screening in Korean hypokalemic periodic paralysis patients: a novel SCN4A Arg672Cys mutation.
}}